Skip to main content

Clinical Trials Using Golcadomide

Review the clinical trials studying golcadomide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-8 of 8

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Status: Active
Location: 12 locations
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Status: Active
Location: 9 locations
Golcadomide and Rituximab as Bridging Therapy for Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma before CAR T-cell Therapy
Status: Active
Location: 7 locations
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Status: Active
Location: 5 locations
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 5 locations
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Status: Active
Location: 3 locations
Obinutuzumab and CC-99282 for the Treatment of Patients with Previously Untreated High Tumor Burden Follicular Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
CC-99282 and Rituximab for the Treatment of Patients who have Received CAR T-Cell Therapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio